Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care

Abramson Cancer Center at Penn Medicine

Status: Active, not recruiting

Conditions: Cancer

Treatments: Behavioral: Offering Additional Resources to Promote Symptom Management

Study type: Interventional

Funder types: Other

Identifiers

NCT05331625

850807

UPCC 11922

Details and patient eligibility

About

This randomized controlled trial will assess the effects on quality of life of two approaches to symptom management among new patients referred to a palliative care oncology clinic.

Enrollment: 208 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Be a new patient at an outpatient palliative care clinic
• Resident of Pennsylvania
• Over 18 years of age

Exclusion criteria

• Prior use of certain symptom focused therapies
• Currently pregnant

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

208 participants in 2 patient groups

Intervention

Experimental group

Description:

Participants in this group will consent to participate in a study about quality of life for patients with cancer seeking outpatient palliative care. They will be seen in a palliative care oncology clinic at which time they will be offered additional resources to promote symptom management. They will be asked to complete a series of surveys every two weeks for 16 weeks which will assess their quality of life, symptoms, and medication use.

Treatment:

Behavioral: Offering Additional Resources to Promote Symptom Management

Usual Care

No Intervention group

Description:

Participants in this group will consent to participate in a study about quality of life for patients with cancer seeking outpatient palliative care. They will be seen in a palliative care oncology clinic where they will receive symptom management and supportive care. They will be asked to complete a series of surveys every two weeks for 16 weeks which will assess their quality of life, symptoms, and medication use.